Key result
An enriched mixture of ginsenosides Rk3 and Rh4 (KG-KH) significantly inhibited renal edema and dysfunction (71.4% BUN, 67.4% creatinine) compared to cisplatin control rats.
Why the study?
Does an enriched mixture of ginsenosides Rk3 and Rh4 protect against cisplatin-induced acute kidney injury in vitro and in vivo?
Population
In vitro model and in vivo rat model of acute renal failure generated by single intraperitoneal injection of…
Comparison
Enriched mixture of ginsenosides Rk3 and Rh4… vs Cisplatin control cells/rats
Design
Preclinical
Authors
Loading...
May warrant preclinical follow-up but should not change cisplatin regimens; leaves open clinical translation from animal data.
Does an enriched mixture of ginsenosides Rk3 and Rh4 protect against cisplatin-induced acute kidney injury in vitro and in vivo?
Ginsenosides Rk3 and Rh4 protect against cisplatin-induced acute kidney injury by restoring intrinsic antioxidant defenses in preclinical models.
Baek et al. (2016) studied Cisplatin-induced acute kidney injury. Enriched mixture of ginsenosides Rk3 and Rh4 (KG-KH) vs. Cisplatin control was evaluated on Cell viability, reactive oxygen species generation, blood urea nitrogen, serum creatinine, antioxidant enzyme activity, and histopathological examination. An enriched mixture of ginsenosides Rk3 and Rh4 (KG-KH) significantly inhibited renal edema and dysfunction (71.4% BUN, 67.4% creatinine) compared to cisplatin control rats.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: